OncoPharm

Latest Episodes:

BELLINI Nov 05, 2020

Show notes

The BELLINI trial of venetoxlax in multiple myeloma was put on hold last year due to increased mortality. It's now published (https://doi.org/10.1016/S1470-2045(20)30525-8), so we take a look at the data and the myriad of supportive care concerns.

Updates On Keynote-426, Ph+ ALL, & Post - AlloHSCT Maintenance Oct 29, 2020

Show notes

Discussing three recent publications: 1. Updated results of Keynote-426 (https://doi.org/10.1016/S1470-2045(20)30436-8) 2. Ph+ ALL tx with dasatinib/prednisone --> blinatumomab (https://www.nejm.org/doi/full/10.1056/NEJMoa2016272) 3. Decitabine + G-CSF to prevent AML relapse following alloHSCT (https://ascopubs.org/doi/pdf/10.1200/JCO.19.03277)

Monthly Immunotherapy Expanded Approvals Update Oct 21, 2020

Show notes

Another month, another 2 expanded FDA-approvals: nivolumab/ipilimumab for malignant pleural mesothelioma and pembrolizumab for relapsed/refractory classical Hodgkin's lymphoma.

Fulvestrant's Fumbled Dosing Oct 15, 2020

Show notes

Fulvestrant's standard dosing is now 500 mg IM on Days 1, 14, 29 & then monthly thereafter. Its initial FDA-approved doing was half that with no loading dose, 250 mg IM monthly. So, how did we come to underdose an antineoplastic for almost a decade?

Dexamethasone Oct 08, 2020

Show notes

Foundations in #OncoPharm returns to discuss everyone's favorite antineoplastic, dexamethasone, which is also an anti-emetic, and an oncology pre-med among other things.

IMpower 110 & Checkmate 153 Oct 01, 2020

Show notes

Another week, another 2 studies of checkpoint inhibitors in NSCLC to talk about. IMpower 110: https://www.nejm.org/doi/full/10.1056/NEJMoa1917346 Checkmate-153: https://ascopubs.org/doi/full/10.1200/JCO.20.00131

ESMO 2020 & Beyond Sep 24, 2020

Show notes

Updates from ESMO 2020 & more on: Bladder Cancer (JAVELIN Bladder 100 & DANUBE) Lung Cancer (ADAURA & CROWN) Breast Cancer (ASCENT, IMPASSION 130/131, monarchE) And the first major publication of drugging the "undrugable" KRAS

TAX 327 Sep 17, 2020

Show notes

The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory. TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720

Pralsetinib Sep 11, 2020

Show notes

We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.

BROCADE3 Sep 03, 2020

Show notes

After brief diatribes on PO azacitidine and COMBI-AD's 5-year non-OS analysis, we focus on BROCADE3 and the background on BRCA-mutated metastatic breast cancer treatment. BROCADE3: https://doi.org/10.1016/S1470-2045(20)30447-2

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected